{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:25:46Z","timestamp":1778718346539,"version":"3.51.4"},"reference-count":35,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14027","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:59:20Z","timestamp":1692795560000},"source":"Crossref","is-referenced-by-count":1,"title":["BR vs. R\u2011miniCHOP in unfit patients with B\u2011cell non\u2011Hodgkin lymphoma: A randomized, two\u2011center, cohort study"],"prefix":"10.3892","volume":"26","author":[{"given":"Dongdong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhong","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430071, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"key20230925111241_b1-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/oxfordjournals.annonc.a058211","article-title":"Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-study group","volume":"3","author":"d'Amore","year":"1992","journal-title":"Ann Oncol"},{"key":"key20230925111241_b2-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b3-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"key20230925111241_b4-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20230925111241_b5-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00432-010-0973-x","article-title":"Charlson comorbidity index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma","volume":"137","author":"Kobayashi","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20230925111241_b6-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: Rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b7-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"key20230925111241_b8-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"key20230925111241_b9-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00277-018-3317-6","article-title":"Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: A multicenter retrospective analysis","volume":"97","author":"Hong","year":"2018","journal-title":"Ann Hematol"},{"key":"key20230925111241_b10-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b11-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2011.09011.x","article-title":"Treatment of the elderly patient with diffuse large B cell lymphoma","volume":"157","author":"Fields","year":"2012","journal-title":"Br J Haematol"},{"key":"key20230925111241_b12-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person: A practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"key20230925111241_b13-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the international society of geriatric oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20230925111241_b14-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the lymphoma Italian foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key20230925111241_b15-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood-2016-03-657379","article-title":"Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues","volume":"127","author":"Cazzola","year":"2016","journal-title":"Blood"},{"key":"key20230925111241_b16-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b17-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20230925111241_b18-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"key20230925111241_b19-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20230925111241_b20-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","article-title":"Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US intergroup study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-IPI)","volume":"151","author":"Advani","year":"2010","journal-title":"Br J Haematol"},{"key":"key20230925111241_b21-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3322\/caac.20059","article-title":"Evaluating the older patient with cancer: Understanding frailty and the geriatric assessment","volume":"60","author":"Pal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"key20230925111241_b22-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/10245332.2018.1509461","article-title":"Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma","volume":"24","author":"Kayamori","year":"2019","journal-title":"Hematology"},{"key":"key20230925111241_b23-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: Results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b24-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: Evidence from a multicenter, retrospective study","volume":"23","author":"Mondello","year":"2018","journal-title":"Oncologist"},{"key":"key20230925111241_b25-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"key20230925111241_b26-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/ajh.24984","article-title":"Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance","volume":"93","author":"Ribes","year":"2018","journal-title":"Am J Hematol"},{"key":"key20230925111241_b27-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00277-012-1503-5","article-title":"Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: Rational, efficacy, and tolerance","volume":"91","author":"Horn","year":"2012","journal-title":"Ann Hematol"},{"key":"key20230925111241_b28-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ejh.13069","article-title":"Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma","volume":"101","author":"Cheng","year":"2018","journal-title":"Eur J Haematol"},{"key":"key20230925111241_b29-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: A phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"key":"key20230925111241_b30-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"key":"key20230925111241_b31-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","article-title":"Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas","volume":"22","author":"Weidmann","year":"2011","journal-title":"Ann Oncol"},{"key":"key20230925111241_b32-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20230925111241_b33-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","article-title":"Novel HDAC inhibitor chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death Dis"},{"key":"key20230925111241_b34-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"key20230925111241_b35-ol-26-4-14027","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41375-019-0442-8","article-title":"Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative\/BCL-2-positive diffuse large B-cell lymphoma","volume":"33","author":"Sasi","year":"2019","journal-title":"Leukemia"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T08:12:46Z","timestamp":1695629566000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14027","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"article-number":"440"}}